Diagnostic accuracy of 68Ga PSMA-PET/CT in newly diagnosed prostate cancer patients

niversity Medical Center Utrecht0 sites100 target enrollmentTBD

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Not specified
Sponsor: niversity Medical Center Utrecht
Enrollment: 100
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Observational non invasive

Investigators

Sponsor

niversity Medical Center Utrecht

Eligibility Criteria

Inclusion Criteria

•1\.Biopsy proven adenocarcinoma of the prostate with an indication for pelvic lymph node dissection (with or without robot\-assisted laparoscopic prostatectomy)
•2\.Mentally competent and understanding of benefits and potential burden of the study

Exclusion Criteria

•1\.History of prior diagnosed or treated PCa.
•2\.Known concomitant malignancies (except Basal Cell Carcinoma of the skin).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting

Not Applicable

Prospective cross-sectional study of 68Ga-PSMA PET/CT in addition to mpMRI in men undergoing 12-month confirmatory biopsy during Active Surveillance for low- or intermediate-risk prostate cancerProstate CancerCancer - Prostate

ACTRN12622000188730St. Vincent's Prostate Cancer Research Centre225

Not yet recruiting

Not Applicable

Diagnostic Accuracy of 68Ga-PSMA PET/CT to identify residual Prostate Cancer Following Focal therapy with Irreversible Electroporation (NanoKnife).Prostate CancerCancer - Prostate

ACTRN12623001082695St Vincent's Private Hospital154

Active, not recruiting

Phase 1

Evaluation of 68Ga-PSMA PET-CT in the initial extension assessment of advanced renal cell carcinomaa prospective, multicenter, open studyrenal cell cancer (RCC)Therapeutic area: Diseases [C] - Cancer [C04]

EUCTR2019-003760-47-FRAssistance Publique Hôpitaux de Marseille44

Active, not recruiting

Phase 1

Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

EUCTR2016-000842-79-BEInstitut Jules Bordet75

Recruiting

Phase 1

68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian CancerOvarian CancerMedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]Therapeutic area: Diseases [C] - Neoplasms [C04]

CTIS2023-505938-98-00Aalborg University Hospital50